Skip to main content
Top
Published in: European Radiology 12/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | Magnetic Resonance

Inter- and intra-reader agreement for gadoxetic acid–enhanced MRI parameter readings in patients with chronic liver diseases

Authors: Lucian Beer, Mattias Mandorfer, Nina Bastati, Sarah Poetter-Lang, Dietmar Tamandl, Dilyana Plamenova Stoyanova, Michael Christoph Elmer, Georg Semmler, Benedikt Simbrunner, Jacqueline C. Hodge, Claude B. Sirlin, Thomas Reiberger, Ahmed Ba-Ssalamah

Published in: European Radiology | Issue 12/2019

Login to get access

Abstract

Objectives

To examine inter- and intra-observer agreement for four simple hepatobiliary phase (HBP)–based scores on gadoxetic acid (GA)–enhanced MRI and their correlation with liver function in patients with mixed chronic liver disease (CLD).

Methods

This single-center, retrospective study included 287 patients (62% male, 38% female, mean age 53.5 ± 13.7 years) with mixed CLD (20.9% hepatitis C, 19.2% alcoholic liver disease, 8% hepatitis B) who underwent GA-enhanced MRI of the liver for clinical care between 2010 and 2015. Relative liver enhancement (RLE), contrast uptake index (CUI), hepatic uptake index (HUI), and liver-to-spleen contrast index (LSI) were calculated by two radiologists independently using unenhanced and GA-enhanced HPB (obtained 20 min after GA administration) images; 50 patients selected at random were reviewed twice by one reader to assess intra-observer reliability. Agreement was assessed by intraclass correlation coefficient (ICC). The albumin-bilirubin (ALBI) score, the model of end-stage liver disease (MELD), and the Child-Turcotte-Pugh (CTP) score were calculated as standards of reference for hepatic function.

Results

Intra-observer ICCs ranged from 0.814 (0.668–0.896) for CUI to 0.969 (0.945–0.983) for RLE. Inter-observer ICCs ranged from 0.777 (0.605–0.874) for HUI to 0.979 (0.963–0.988) for RLE. All HBP-based scores correlated significantly (all p < 0.001) with the ALBI, MELD, and CTP scores and were able to discriminate patients with a MELD score ≥ 15 versus ≤ 14, with area under the curve values ranging from 0.760 for RLE to 0.782 for HUI.

Conclusion

GA-enhanced, MRI-derived, HBP-based parameters showed excellent inter- and intra-observer agreement. All HBP-based parameters correlated with clinical and laboratory scores of hepatic dysfunction, with no significant differences between each other.

Key Points

• Radiological parameters that quantify the hepatic uptake of gadoxetic acid are highly reproducible.
• These parameters can be used interchangeably because they correlate with each other and with scores of hepatic dysfunction.
• Assessment of these parameters may be helpful in monitoring disease progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kochanek KD, Murphy SL (2016) National Vital Statistic Report 65 Kochanek KD, Murphy SL (2016) National Vital Statistic Report 65
2.
go back to reference Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRef Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRef
3.
go back to reference Ahmed A, Wong RJ, Harrison SA (2015) Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 13:2062–2070CrossRef Ahmed A, Wong RJ, Harrison SA (2015) Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 13:2062–2070CrossRef
4.
go back to reference Mathurin P, Bataller R (2015) Trends in the management and burden of alcoholic liver disease. J Hepatol 62:S38–S46CrossRef Mathurin P, Bataller R (2015) Trends in the management and burden of alcoholic liver disease. J Hepatol 62:S38–S46CrossRef
5.
go back to reference Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58:593–608CrossRef Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58:593–608CrossRef
6.
go back to reference Mandorfer M, Kozbial K, Schwabl P et al (2016) Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 65:692–699CrossRef Mandorfer M, Kozbial K, Schwabl P et al (2016) Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 65:692–699CrossRef
7.
go back to reference Mandorfer M, Kozbial K, Freissmuth C et al (2015) Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther 42:707–718CrossRef Mandorfer M, Kozbial K, Freissmuth C et al (2015) Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther 42:707–718CrossRef
8.
go back to reference Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468–475CrossRef Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468–475CrossRef
9.
go back to reference Schwabl P, Mandorfer M, Steiner S et al (2017) Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther 45:139–149CrossRef Schwabl P, Mandorfer M, Steiner S et al (2017) Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther 45:139–149CrossRef
10.
go back to reference Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A (2013) Liver failure after major liver resection: risk assessment by using preoperative gadoxetic acid–enhanced 3-T MR imaging. Radiology 269:777–786CrossRef Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A (2013) Liver failure after major liver resection: risk assessment by using preoperative gadoxetic acid–enhanced 3-T MR imaging. Radiology 269:777–786CrossRef
11.
go back to reference Wiesner R, Edwards E, Freeman R et al (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124:91–96CrossRef Wiesner R, Edwards E, Freeman R et al (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124:91–96CrossRef
13.
go back to reference De Gasperi A, Mazza E, Prosperi M (2016) Indocyanine green kinetics to assess liver function: ready for a clinical dynamic assessment in major liver surgery? World J Hepatol 8:355CrossRef De Gasperi A, Mazza E, Prosperi M (2016) Indocyanine green kinetics to assess liver function: ready for a clinical dynamic assessment in major liver surgery? World J Hepatol 8:355CrossRef
14.
go back to reference Van Beers BE, Garteiser P, Leporq B, Rautou P-E, Valla D (2017) Quantitative imaging in diffuse liver diseases Seminars in liver disease. Thieme Medical Publishers, Stuttgart, pp 243–258 Van Beers BE, Garteiser P, Leporq B, Rautou P-E, Valla D (2017) Quantitative imaging in diffuse liver diseases Seminars in liver disease. Thieme Medical Publishers, Stuttgart, pp 243–258
15.
go back to reference Haimerl M, Fuhrmann I, Poelsterl S et al (2018) Gd-EOB-DTPA-enhanced T1 relaxometry for assessment of liver function determined by real-time 13 C-methacetin breath test. Eur Radiol:1–10 Haimerl M, Fuhrmann I, Poelsterl S et al (2018) Gd-EOB-DTPA-enhanced T1 relaxometry for assessment of liver function determined by real-time 13 C-methacetin breath test. Eur Radiol:1–10
16.
go back to reference Park CC, Nguyen P, Hernandez C et al (2017) Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152:598–607 e592CrossRef Park CC, Nguyen P, Hernandez C et al (2017) Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 152:598–607 e592CrossRef
17.
go back to reference Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357CrossRef Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357CrossRef
19.
go back to reference Lewin M, Poujol-Robert A, Boëlle PY et al (2007) Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46:658–665CrossRef Lewin M, Poujol-Robert A, Boëlle PY et al (2007) Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46:658–665CrossRef
20.
go back to reference Yoon JH, Lee JM, Kang H-j et al (2018) Quantitative assessment of liver function by using gadoxetic acid–enhanced MRI: hepatocyte uptake ratio. Radiology:180753 Yoon JH, Lee JM, Kang H-j et al (2018) Quantitative assessment of liver function by using gadoxetic acid–enhanced MRI: hepatocyte uptake ratio. Radiology:180753
21.
go back to reference Haimerl M, Probst U, Poelsterl S et al (2018) Hepatobiliary MRI: signal intensity based assessment of liver function correlated to (13)C-methacetin breath test. Sci Rep 8:9078CrossRef Haimerl M, Probst U, Poelsterl S et al (2018) Hepatobiliary MRI: signal intensity based assessment of liver function correlated to (13)C-methacetin breath test. Sci Rep 8:9078CrossRef
22.
go back to reference Sourbron S, Sommer WH, Reiser MF, Zech CJ (2012) Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Radiology 263:874–883CrossRef Sourbron S, Sommer WH, Reiser MF, Zech CJ (2012) Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging. Radiology 263:874–883CrossRef
23.
go back to reference Ba-Ssalamah A, Bastati N, Wibmer A et al (2017) Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we? J Magn Reson Imaging 45:646–659CrossRef Ba-Ssalamah A, Bastati N, Wibmer A et al (2017) Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we? J Magn Reson Imaging 45:646–659CrossRef
24.
go back to reference Haimerl M, Verloh N, Zeman F et al (2017) Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep 7:43347CrossRef Haimerl M, Verloh N, Zeman F et al (2017) Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep 7:43347CrossRef
25.
go back to reference Geisel D, Lüdemann L, Fröling V et al (2015) Imaging-based evaluation of liver function: comparison of 99mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur Radiol 25:1384–1391CrossRef Geisel D, Lüdemann L, Fröling V et al (2015) Imaging-based evaluation of liver function: comparison of 99mTc-mebrofenin hepatobiliary scintigraphy and Gd-EOB-DTPA-enhanced MRI. Eur Radiol 25:1384–1391CrossRef
26.
go back to reference Takatsu Y, Kobayashi S, Miyati T, Shiozaki T (2016) Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin–bilirubin grading system. Eur J Radiol 85:2206–2210CrossRef Takatsu Y, Kobayashi S, Miyati T, Shiozaki T (2016) Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin–bilirubin grading system. Eur J Radiol 85:2206–2210CrossRef
27.
go back to reference Nakagawa M, Namimoto T, Shimizu K et al (2017) Measuring hepatic functional reserve using T1 mapping of Gd-EOB-DTPA enhanced 3T MR imaging: a preliminary study comparing with 99m Tc GSA scintigraphy and signal intensity based parameters. Eur J Radiol 92:116–123CrossRef Nakagawa M, Namimoto T, Shimizu K et al (2017) Measuring hepatic functional reserve using T1 mapping of Gd-EOB-DTPA enhanced 3T MR imaging: a preliminary study comparing with 99m Tc GSA scintigraphy and signal intensity based parameters. Eur J Radiol 92:116–123CrossRef
28.
go back to reference Sandrasegaran K, Cui E, Elkady R et al (2018) Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis? Eur Radiol:1–10 Sandrasegaran K, Cui E, Elkady R et al (2018) Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis? Eur Radiol:1–10
29.
go back to reference Bastati N, Feier D, Wibmer A et al (2014) Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid–enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271:739–747CrossRef Bastati N, Feier D, Wibmer A et al (2014) Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid–enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271:739–747CrossRef
30.
go back to reference Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558CrossRef Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33:550–558CrossRef
31.
go back to reference Graziadei I, Zoller H, Fickert P et al (2016) Indications for liver transplantation in adults. Wien Klin Wochenschr 128:679–690CrossRef Graziadei I, Zoller H, Fickert P et al (2016) Indications for liver transplantation in adults. Wien Klin Wochenschr 128:679–690CrossRef
32.
go back to reference Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163CrossRef Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155–163CrossRef
33.
34.
go back to reference Besa C, Wagner M, Lo G et al (2017) Detection of liver fibrosis using qualitative and quantitative MR elastography compared to liver surface nodularity measurement, gadoxetic acid uptake, and serum markers. J Magn Reson Imaging Besa C, Wagner M, Lo G et al (2017) Detection of liver fibrosis using qualitative and quantitative MR elastography compared to liver surface nodularity measurement, gadoxetic acid uptake, and serum markers. J Magn Reson Imaging
35.
go back to reference Verloh N, Haimerl M, Zeman F et al (2014) Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 tesla. Eur Radiol 24:1013–1019CrossRef Verloh N, Haimerl M, Zeman F et al (2014) Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 tesla. Eur Radiol 24:1013–1019CrossRef
36.
go back to reference Jang Y-J, Cho SH, Bae JH et al (2013) Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI. Ann Hepatol 12 Jang Y-J, Cho SH, Bae JH et al (2013) Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI. Ann Hepatol 12
37.
go back to reference Motosugi U, Ichikawa T, Oguri M et al (2011) Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 29:1047–1052CrossRef Motosugi U, Ichikawa T, Oguri M et al (2011) Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 29:1047–1052CrossRef
38.
go back to reference Okubo H, Mogami M, Ozaki Y et al (2013) Liver function test by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging with consideration of intrahepatic regional differences. Hepatogastroenterology 60:1547–1551PubMed Okubo H, Mogami M, Ozaki Y et al (2013) Liver function test by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging with consideration of intrahepatic regional differences. Hepatogastroenterology 60:1547–1551PubMed
39.
go back to reference Chan AW, Chan RC, Wong GL et al (2015) New simple prognostic score for primary biliary cirrhosis: albumin-bilirubin score. J Gastroenterol Hepatol 30:1391–1396CrossRef Chan AW, Chan RC, Wong GL et al (2015) New simple prognostic score for primary biliary cirrhosis: albumin-bilirubin score. J Gastroenterol Hepatol 30:1391–1396CrossRef
41.
go back to reference Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649CrossRef Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649CrossRef
42.
go back to reference Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470CrossRef Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470CrossRef
43.
go back to reference Peng Y, Qi X, Guo X (2016) Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore) 95:e2877CrossRef Peng Y, Qi X, Guo X (2016) Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore) 95:e2877CrossRef
44.
go back to reference Hiraoka A, Kumada T, Kudo M et al (2017) Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. Liver Cancer 6:204–215CrossRef Hiraoka A, Kumada T, Kudo M et al (2017) Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. Liver Cancer 6:204–215CrossRef
Metadata
Title
Inter- and intra-reader agreement for gadoxetic acid–enhanced MRI parameter readings in patients with chronic liver diseases
Authors
Lucian Beer
Mattias Mandorfer
Nina Bastati
Sarah Poetter-Lang
Dietmar Tamandl
Dilyana Plamenova Stoyanova
Michael Christoph Elmer
Georg Semmler
Benedikt Simbrunner
Jacqueline C. Hodge
Claude B. Sirlin
Thomas Reiberger
Ahmed Ba-Ssalamah
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 12/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-019-06182-z

Other articles of this Issue 12/2019

European Radiology 12/2019 Go to the issue